Stocktoria
CRESCENT BIOPHARMA, INC. CBIO
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2014-01-10
CRESCENT BIOPHARMA, INC. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -1407.5% | — | -392752.9% | -63204.4% | -5470.7% |
| Net margin | -1419.6% | — | -368994.2% | -62251.7% | -5469.0% |
| FCF margin | -668.1% | — | -349013.0% | -62055.6% | -4958.3% |
| Return on assets | -64.1% | -106.4% | -81.4% | -90.1% | -67.2% |
| Return on equity | -75.8% | 244.7% | -96.1% | -108.8% | -77.7% |
| Current ratio | 6.56 | 3.62 | 6.41 | 5.71 | 7.68 |
| Revenue growth | — | — | -86.7% | -93.5% | -88.6% |
Source: SEC EDGAR filings · CIK 0001253689 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.